Type 2 diabetes
is a condition in which your body does not make enough insulin, and
the insulin that your body makes does not lower your blood sugar the
way it should. The result is a high level of glucose in the
blood
The active substance in RYBELSUS®,
semaglutide, is a ‘GLP-1 receptor agonist’. It acts in the same way as
GLP-1 (a hormone produced in the gut) by increasing the amount of
insulin that the pancreas releases in response to food. This can help
with the control of blood glucose levels
The term HbA1c refers to glycated haemoglobin. It develops when haemoglobin, a protein within red blood cells that carries oxygen throughout your body, joins with glucose in the blood, becoming ‘glycated’
HbA1c measurement gives an overall picture of what our average blood sugar levels have been over a period of weeks or months. As part of your type 2 diabetes management, you have been prescribed RYBELSUS® to help you gain better control of your blood sugar levels by lowering your blood sugar to help you reach your HbA1c goal
UK20RYB00195 | February 2021
▼ This medicinal product is subject to
additional monitoring. This will allow quick identification of
new safety information.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist
or nurse. This includes any possible side effects not listed in the
package leaflet. You can also report side effects directly via the
Yellow Card Scheme at www.mhra.gov.uk/yellowcard↗. By reporting side effects you can help provide more
information on the safety of this medicine.
© 2022 Novo Nordisk. All rights reserved
